



Disclosure of Relevant Financial Relationships

NMIBC Guideline Update for APPs: What's Changed and Why it Matters

All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible companies during the previous 24 months.

An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The AUA must determine if the individual's relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments. All relevant financial relationships listed below have been mitigated.

Faculty

Name	Company Name	Relationship Type	End Date
Clark, Peter Earl	No relevant financial relationships to disclose		
Bupathi, Manoj	Bristol Myers Squibb	Consultant or Advisor	Current
	AstraZeneca	Consultant or Advisor	Current
	Exelixis	Consultant or Advisor	Current
	Merck	Consultant or Advisor	Current
	Genentech	Consultant or Advisor	Current
	Janssen	Consultant or Advisor	Current
	Bayer	Meeting Participant or Lecturer	Current
	AIQ Solutions	Meeting Participant or Lecturer	Current
	Merck Serono	Meeting Participant or Lecturer	Current
	Pfizer	Meeting Participant or Lecturer	Current
	Astellas Pharma	Meeting Participant or Lecturer	Current
	Janssen Oncology	Meeting Participant or Lecturer	Current
	Novartis	Consultant or Advisor	Current
	Amgen	Consultant or Advisor	Current
	Xencore	Consultant or Advisor	Current
	Johnson & Johnson	Consultant or Advisor	Current
Mazzarella, Brian C.	Neotract/Teleflex	Scientific Study or Trial	Current
	Urotronic	Scientific Study or Trial	Current
	Janssen	Scientific Study or Trial	Current
	Candel Therapeutics	Scientific Study or Trial	Current
	Zenflow	Scientific Study or Trial	Current
	Neuspera	Scientific Study or Trial	Current
	Butterfly Medical	Scientific Study or Trial	Current
	Proverum Medical	Scientific Study or Trial	Current
	CG Oncology	Scientific Study or Trial	Current
	Francis Medical	Scientific Study or Trial	Current
	Astra Zeneca	Scientific Study or Trial	Current
	Myovant	Scientific Study or Trial	Current
	Merck	Scientific Study or Trial	Current



Disclosure of Relevant Financial Relationships

NMIBC Guideline Update for APPs: What's Changed and Why it Matters

Name	Company Name	Relationship Type	End Date
	enGene	Scientific Study or Trial	Current
	ImmunityBio	Scientific Study or Trial	Current
	Rivermark	Scientific Study or Trial	Current
	Johnson & Johnson	Consultant or Advisor	Current
	Astellas	Scientific Study or Trial	Current
	Bristol Meyers Squibb	Scientific Study or Trial	Current
	Blue Earth Diagnostics	Scientific Study or Trial	Current
	ALPFA	Scientific Study or Trial	Current
	Clarity Pharma	Scientific Study or Trial	Current
	Ferring Pharmaceuticals	Scientific Study or Trial	Current
	Novartis	Scientific Study or Trial	Current
	Procept	Scientific Study or Trial	Current
	Tyra	Scientific Study or Trial	Current
	UroGen	Scientific Study or Trial	Current
	Veracyte	Consultant or Advisor	Current
Merrill, Suzanne B.	Photocure	Consultant or Advisor	Current
	Johnson & Johnson	Meeting Participant or Lecturer	Current
	EnGene	Consultant or Advisor	Current
	UroGen	Meeting Participant or Lecturer	Current
	Pfizer	Consultant or Advisor	Current
	Astellas	Meeting Participant or Lecturer	Current

All AUA staff associated with this committee have nothing to disclose.